ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age

L. Wang, J. Motter, S. Bae, D. Segev, M. McAdams DeMarco

Johns Hopkins University, Baltimore, MD

Meeting: 2020 American Transplant Congress

Abstract number: 8

Keywords: Immunosuppression, Induction therapy, Kidney transplantation, Malignancy

Session Information

Session Name: Kidney Immunosuppression: Induction Therapy

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

*Purpose: Adult kidney-transplant (KT) recipients have a differential risk of malignancies based on their induction immunosuppression (IS) therapy. However, older recipients are more likely to experience immunosenescense and therefore, may have a different risk of malignancy than younger recipients. We compared the risk of incident malignancy among younger (18-64) and older (≥65) KT recipients by use of the two most common induction IS agents: anti-thymocyte globulin (ATG, rATG and eATG) and interleukin-2 receptor antagonist (IL-2 RA, basiliximab and daclizumab).

*Methods: A total of 66,700 adult (age≥ 18) first-time KT recipients were identified using either ATG (n=40,443) or IL2-RA (n=26,327) between January 1, 1999 and December 31, 2014 with the United States Renal Data System linked to Medicare claims. Kaplan-Meier estimator was used to generate the cumulative incidence of first-diagnosed malignancy after KT. The Cox proportional hazard model was used to estimate hazard ratios (HR) of any and specific incident malignancy comparing ATG to IL-2 RA. All models incorporated weighting with inverse propensity score to adjust for confounders. Propensity scores for each individual was generated as the average of estimated probabilities from logistic regression models among multiple imputation datasets for missing values in putative confounders.

*Results: The 6-month, 1-year and 3-year cumulative incidences of any malignancy were 2.32%, 4.46% and 11.95% respectively. In overall, the use of ATG induction was associated with higher risk of post KT malignancy (HR 1.11, 95% CI 1.05-1.17, p<0.001) compared with IL-2 RA induction. This effect of IS on incident malignancy was similar among younger recipients (HR 1.12, 95% CI 1.06-1.18, p<0.001) and older recipients (HR 1.07, 95% CI 1.01-1.14, p<0.05; interaction p=0.392). For specific malignancy, ATG induction is associated with higher risk of post KT skin malignancy (HR 1.22, 95% CI 1.12-1.33, p<0.001), while there was no significant evidence suggesting that ATG induction is associated with higher risk of kidney malignancy (HR 1.03, 95% CI 0.89-1.18, p=0.684) or lymphoma malignancy (HR 1.12, 95% CI 0.99-1.27, p=0.064).

*Conclusions: Compared with IL-2 RA induction, ATG induction is associated with elevated risk of post-transplant malignancy; these effects did not differ by age. Transplant centers do not need to tailor induction IS by age to mitigate malignancy risk.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wang L, Motter J, Bae S, Segev D, DeMarco MMcAdams. Incident Malignancies among Post Kidney-Transplant Patients by Type of Induction Immunosuppression and by Age [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/incident-malignancies-among-post-kidney-transplant-patients-by-type-of-induction-immunosuppression-and-by-age/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences